Gossamer Bio Announces Participation in 9th Annual SVB Leerink Global Healthcare Conference

On February 18, 2020 Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, reported that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25 at 9:30 a.m. ET (Press release, Gossamer Bio, FEB 18, 2020, View Source [SID1234554446]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the "Events and Presentations" page in the "Investors" section of the company’s website at View Source A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

On February 18, 2020 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, reported participation at the following upcoming conferences (Press release, Rocket Pharmaceuticals, FEB 18, 2020, View Source [SID1234554445]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

9th Annual SVB Leerink Global Healthcare Conference, New York, N.Y.
Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, February 25, 2020, at 10:30 a.m. Eastern Time.
Cowen’s 40th Annual Health Care Conference, Boston, M.A.
Gaurav Shah, M.D., President and CEO, is scheduled to present on Monday, March 2, 2020, at 2:10 p.m. Eastern Time.
Annual Barclays Global Healthcare Conference, Miami, F.L.
Tuesday, March 10, 2020
Oppenheimer’s 30th Annual Healthcare Conference, New York, N.Y.
Gaurav Shah, M.D., President and CEO, is scheduled to present on Wednesday, March 18, 2020, at 11:30 a.m. Eastern Time
A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

Epizyme Announces Date of Fourth Quarter and Full Year 2019 Results and Presentations at Upcoming Investor Conferences

On February 18, 2020 Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, reported that management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results and present at upcoming investor conferences (Press release, Epizyme, FEB 18, 2020, View Source [SID1234554444]). Details of the events are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth Quarter and Full-Year 2019 Financial Results: Management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results on Monday, Feb. 24, 2020 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 9045277.

Upcoming Investor Conference Presentations: Management will present at the following upcoming conferences:
9th Annual SVB Leerink Global Healthcare Conference on Tuesday, Feb. 25, 2020 at 1:00 p.m. ET in New York City;
Cowen and Company’s 40th Annual Healthcare Conference on Monday, March 2, 2020 at 3:30 p.m. ET in Boston;
Barclays Global Healthcare Conference on Tuesday, March 10, 2020 at 2:05 p.m. ET in Miami; and,
Oppenheimer 30th Annual Healthcare Conference on Tuesday, March 17, 2020 at 3:55 p.m. ET in New York City.
Live webcasts will be available in the investor section of the company’s website at www.epizyme.com. The webcasts will be archived for 60 days following the call and presentations.

Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference

On February 18, 2020 Horizon Therapeutics plc (Nasdaq: HZNP) reported that the Company will participate in the following conference in March (Press release, Horizon Therapeutics, FEB 18, 2020, https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-present-cowen-and-company-40th-annual [SID1234554443]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company 40th Annual Health Care Conference

Date: Tuesday, Mar. 3, 2020
Presentation Time: 12 p.m. ET
Location: Boston
The conference presentation will be webcast live and may be accessed by visiting Horizon’s website at View Source A replay of the webcast will be available for the event.

EDAP Showcases Focal One at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer

On February 18, 2020 EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, reported that the company recently showcased its Focal One high intensity focused ultrasound (HIFU) device at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which was held February 9-11 in Washington, DC (Press release, EDAP TMS, FEB 18, 2020, View Source [SID1234554442]). This marks the first time that the symposium was held in the U.S. since FDA clearance of Focal One in June 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have been featured in this very prestigious and highly specialized symposium on focal imaging and therapy that attracts urology thought leaders from around the world," said Marc Oczachowski, Chief Executive Officer of EDAP. "This annual gathering is the most important and referenced event for focal therapy in urology disorders, a rapidly growing modality for the treatment of prostate and kidney cancer, and we were extremely pleased to see the prominent positioning of HIFU in addressing this focal therapy strategy. As a recognized leader in the use of targeted ultrasound for this and possibly other indications in development, we have participated at this symposium since its inception and will continue to do so in the future."

This year’s gathering featured several presentations highlighting the Focal One technology and positive results that the process delivers, including presentations by Dr. Rafael Sanchez-Salas, MD, Department of Urology, L’Institut Mutualiste Montsouris, Université Paris Descartes, Paris, France. Dr. Sanchez-Salas is a highly regarded Robotic Urologist Surgeon and long-time champion of EDAP’s Focal Therapy technologies.

EDAP will provide a detailed commercial and clinical update during the company’s upcoming fourth quarter 2019 results conference call.

About the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer

This three-day symposium incorporates real-time imaging into the diagnostic and treatment strategies for prostate and kidney cancer. Taking part in this meeting hands attendees the opportunity to gain valuable insights through the interactive scientific program: state-of-the art lectures, video demonstrations and hands-on workshops, all delivered by a world-class faculty. The intimate meeting size allows everyone to network with faculty and exchange opinions and experiences.